

# Vivek Roy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5243773/publications.pdf>

Version: 2024-02-01

125  
papers

2,332  
citations

411340

20  
h-index

252626

46  
g-index

126  
all docs

126  
docs citations

126  
times ranked

3681  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	1.4	440
2	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood, 2015, 125, 443-448.	0.6	195
3	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.	0.6	144
4	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.	0.6	119
5	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	1.4	115
6	Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1375-1381.	2.0	112
7	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
8	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	1.4	106
9	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	1.3	81
10	Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Medicine, 2017, 6, 2876-2885.	1.3	63
11	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	0.6	51
12	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal, 2019, 9, 75.	2.8	43
13	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2019, 54, 204-211.	1.3	41
14	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology, 2018, 93, 649-654.	2.0	40
15	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer, 2018, 124, 1710-1721.	2.0	40
16	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	1.4	32
17	AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. British Journal of Haematology, 2014, 164, 352-365.	1.2	30
18	Artifactual Laboratory Abnormalities in Patients with Paraproteinemia. Southern Medical Journal, 2009, 102, 167-170.	0.3	26

#	ARTICLE	IF	CITATIONS
19	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 76-82.	2.0	26
20	Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. <i>Cancer</i> , 2016, 122, 618-625.	2.0	21
21	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1906-1913.	2.0	21
22	Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients. <i>Blood</i> , 2013, 122, 758-758.	0.6	21
23	Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. <i>Transfusion</i> , 2008, 48, 1106-1114.	0.8	20
24	A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 540-544.	0.6	19
25	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 1106-1110.	2.0	19
26	Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e449-e455.	0.2	19
27	Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 31-38.	1.1	18
28	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2018, 183, 196-211.	1.2	16
29	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	0.6	16
30	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 36.	2.8	14
31	mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).. <i>Blood</i> , 2007, 110, 2555-2555.	0.6	14
32	Dual roles of autologous CD8+ T cells in hematopoietic progenitor cell mobilization and engraftment. <i>Transfusion</i> , 2015, 55, 1758-1765.	0.8	12
33	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
34	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	0.6	12
35	Nuances in the Management of Older People With Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 241-251.	1.2	11
36	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. <i>JCO Oncology Practice</i> , 2020, 16, e341-e349.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 165.e1-165.e11.	0.6	11
38	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. <i>Blood</i> , 2012, 120, 194-194.	0.6	11
39	Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. <i>Cancers</i> , 2021, 13, 5770.	1.7	11
40	Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 619-623.	0.2	10
41	Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity. <i>Blood</i> , 2012, 120, 76-76.	0.6	9
42	The Novel Proteasome Inhibitor MLN2238 (Ixazomib) Induces Death In CLL Cells In Vitro and Potentiates Lethality Of Fludarabine and The BCL2 Inhibitor At-101. <i>Blood</i> , 2013, 122, 4189-4189.	0.6	9
43	Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone. <i>Annals of Hematology</i> , 2016, 95, 671-672.	0.8	8
44	Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 564-570.	2.0	8
45	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	0.6	8
46	Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome. <i>Blood</i> , 2018, 132, 1911-1911.	0.6	8
47	Autologous Stem Cell Transplant for AL Amyloidosis. <i>Bone Marrow Research</i> , 2012, 2012, 1-5.	1.7	7
48	Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization. <i>Cytotherapy</i> , 2020, 22, 16-20.	0.3	7
49	Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality. <i>Journal of Clinical Apheresis</i> , 2019, 34, 39-43.	0.7	6
50	Marked Elliptocytosis in Myelodysplastic Syndromes (MDS) Is Associated to Deletion of Chromosome 20q. <i>Blood</i> , 2005, 106, 4927-4927.	0.6	6
51	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	6
52	Use of KR2-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. <i>Case Reports in Hematology</i> , 2020, 2020, 1-6.	0.3	5
53	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 141-146.	0.6	5
54	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360.	0.2	5

#	ARTICLE	IF	CITATIONS
55	Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells. <i>Blood</i> , 2016, 128, 3018-3018.	0.6	5
56	Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant. <i>Annals of Hematology</i> , 2017, 96, 2125-2126.	0.8	4
57	Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 347-350.	1.2	4
58	Primary Cutaneous T-Cell Lymphoblastic Lymphoma: Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2019, 2019, 1-6.	0.3	4
59	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156.	2.8	4
60	Utilization of radiation therapy in multiple myeloma: trends and changes in practice. <i>Annals of Hematology</i> , 2021, 100, 735-741.	0.8	4
61	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years. <i>Blood</i> , 2011, 118, 3963-3963.	0.6	4
62	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015, 126, 703-703.	0.6	4
63	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. <i>Blood</i> , 2017, 130, 864-864.	0.6	4
64	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	0.6	4
65	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	1.1	3
66	Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL). <i>Blood</i> , 2015, 126, 5299-5299.	0.6	3
67	Trends in Disease Presentation, Management, Cost of Care and Outcomes: A Comprehensive Look at Racial Disparities in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 3544-3544.	0.6	3
68	Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2727-2730.	0.6	2
69	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <i>Anti-Cancer Drugs</i> , 2019, 30, 859-865.	0.7	2
70	Ixazomib and lenalidomide maintenance therapy in multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 851-853.	0.8	2
71	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.2	2
72	Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis. <i>Blood</i> , 2019, 134, 71-71.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Severe Acute Hemolytic Transfusion Reaction Following ABO-Mismatched Platelet Transfusion: Should ABO-Mismatched Platelet Transfusion Policy Be Evaluated.. Blood, 2004, 104, 4095-4095.	0.6	2
74	Melphalan (M), Prednisone (P) and Lenalidomide (R) Combination (MPR) for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation.. Blood, 2006, 108, 3558-3558.	0.6	2
75	Autologous Hemopoietic Stem Cell Transplantation Is a Viable Treatment Option for Post Liver Transplant Lymphoproliferative Disorder: A Case Report.. Blood, 2006, 108, 5447-5447.	0.6	2
76	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	0.6	2
77	Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14 Is Lethal To Waldenstr�m's Macroglobulinemia Cells. Blood, 2013, 122, 1823-1823.	0.6	2
78	Persistent Racial/Ethnic Disparities in Outcomes for Multiple Myeloma: A SEER-Database Update. Blood, 2016, 128, 1191-1191.	0.6	2
79	Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Compass Study Database. Blood, 2016, 128, 4432-4432.	0.6	2
80	Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma. Blood, 2016, 128, 4480-4480.	0.6	2
81	Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation. Blood, 2015, 126, 2754-2754.	0.6	2
82	Plamotamab (XmAb<sup>� <sup&gt;13676< sup="">&lt;/sup&gt;) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr�m macroglobulinemia. Leukemia and Lymphoma, 2022, 63, 738-742.</sup&gt;13676<>	0.6	2
83	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). Blood, 2020, 136, 29-30.	0.6	2
84	Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 155-160.	0.6	1
85	Impact of Depression and Anxiety on Opioid Use�n Hospitalized Hematopoietic Cell Transplantation Recipients. Psychosomatics, 2020, 61, 363-370.	2.5	1
86	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	0.6	1
87	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.	0.6	1
88	Racial Disparity in Drug Utilization Among Multiple Myeloma Patients: A SEER Medicare Analysis. Blood, 2016, 128, 3542-3542.	0.6	1
89	Dual Roles of CD8+ T Cell In Hematopoietic Progenitor Cell Mobilization and Engraftment. Blood, 2010, 116, 349-349.	0.6	1
90	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. Blood, 2010, 116, 987-987.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Financial Burden In Recipients Of Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 721-721.	0.6	1
92	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. Blood, 2015, 126, 1839-1839.	0.6	1
93	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. Blood, 2018, 132, 5873-5873.	0.6	1
94	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). Blood, 2019, 134, 5343-5343.	0.6	1
95	Clinical Experience with Nanoparticle Albumin Bound (Nab) Paclitaxel (Abraxane®). Frontiers in Nanobiomedical Research, 2014, , 541-556.	0.1	0
96	Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. Journal of Oncology Pharmacy Practice, 2022, 28, 425-433.	0.5	0
97	Platelet Count Is a Sensitive Predictor of Bone Marrow Reserve and Autologous Peripheral Blood Progenitor Cell Mobilization.. Blood, 2005, 106, 5280-5280.	0.6	0
98	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. Blood, 2010, 116, 3047-3047.	0.6	0
99	Lenalidomide Enhances Clonogenic Activity, Proliferation and Erythroid Lineage Commitment of CD34+ Progenitor Cells While It Is Cytotoxic to CD34- Accessory Cells.. Blood, 2010, 116, 1184-1184.	0.6	0
100	Allogeneic Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. Blood, 2012, 120, 2850-2850.	0.6	0
101	Novel Proteasome Inhibitors Induce Mitochondrial Destabilization and Activate Caspase Mediated Apoptosis In Preclinical Models Of Pediatric B-Cell Cancers. Blood, 2013, 122, 5140-5140.	0.6	0
102	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	0.6	0
103	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. Blood, 2013, 122, 1928-1928.	0.6	0
104	The Deubiquitinating Enzymes Of The 19S Proteasome Offer Novel Therapeutic Opportunity In Bortezomib Resistant Waldenström's Macroglobulinemia. Blood, 2013, 122, 4426-4426.	0.6	0
105	Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199. Blood, 2015, 126, 4839-4839.	0.6	0
106	A Single Institution Study of Allogeneic Hematopoietic Stem Cell Transplant for MDS and AML in Patients 60 Years of Age and Older: Impact of Disease Risk Index and Secondary Disease. Blood, 2015, 126, 5532-5532.	0.6	0
107	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	0.6	0
108	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. Blood, 2016, 128, 4653-4653.	0.6	0



#	ARTICLE	IF	CITATIONS
109	Psychiatric Comorbidities Are Associated with Increased Cost of Care and Healthcare Utilization in Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016, 128, 1238-1238.	0.6	0
110	Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities. <i>Blood</i> , 2017, 130, 860-860.	0.6	0
111	Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities. <i>Blood</i> , 2018, 132, 4867-4867.	0.6	0
112	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. <i>Blood</i> , 2018, 132, 2113-2113.	0.6	0
113	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4869-4869.	0.6	0
114	Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States. <i>Blood</i> , 2018, 132, 4861-4861.	0.6	0
115	Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US). <i>Blood</i> , 2018, 132, 4765-4765.	0.6	0
116	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. <i>Blood</i> , 2018, 132, 4764-4764.	0.6	0
117	Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States. <i>Blood</i> , 2018, 132, 4868-4868.	0.6	0
118	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	0.6	0
119	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588.	0.6	0
120	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. <i>Blood</i> , 2019, 134, 5610-5610.	0.6	0
121	Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2742-2742.	0.6	0
122	A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT). <i>Blood</i> , 2021, 138, 3893-3893.	0.6	0
123	Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
124	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	0.6	0
125	Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients. <i>Blood</i> , 2020, 136, 39-40.	0.6	0